Iambic Therapeutics

We are pleased to release today the technical report for NeuralPlexer3 (NP3), our new state-of-the-art generative model for protein-ligand structure prediction. NP3 advances the field of AI-driven drug discovery, providing researchers precise detail on small molecule/protein interactions. NP3 also provides greater speed and prediction accuracy than existing models on all biomolecular interaction types (proteins, nucleic acids, ligands, ions, and post-translational modifications). In a fast moving field, we feel that providing a transparent mechanism for head-to-head comparisons is essential for meaningful scientific progress. To that end, today we also shared code for our primary benchmarking approach on GitHub. By supporting target validation, structural refinement, and atom-level interaction analysis, NP3 bridges critical gaps in AI-driven drug discovery, empowering researchers to navigate the complexities of therapeutic development with greater precision and speed to accelerate therapeutic innovation. https://lnkd.in/gQf4iikb https://lnkd.in/gf3uy_SM #AI #GenAI #BioTech #Innovation #NeuralPLexer

We're thrilled to welcome Peter Olson, Ph.D., as our Chief Scientific Officer. With exceptional experience in cancer drug discovery and development, including work on several marketed therapies, his leadership will help drive our efforts to advance and expand our pipeline of AI-discovered clinical candidates in oncology and beyond. https://lnkd.in/gd-4UzV5 #AI #MachineLearning #oncology #DrugDiscovery

Join our CEO Thomas Miller at the #BiocomCEOSummit for a panel on Unlocking the Future of Drug Development: The Power of AI. Tom will share insights into the latest breakthroughs transforming drug discovery and development, including Enchant, our newly unveiled multimodal AI model designed to predict clinical outcomes from the earliest stages of drug discovery. #AI #BioTech #DrugDiscovery #MachineLearning

Iambic’s newly introduced multi-modal AI model for drug discovery and development, called Enchant, is designed to bring higher quality medicines to patients faster by predicting clinical outcomes from the earliest stages of discovery -- potentially eliminating years of preclinical discovery and accelerating clinical trial timelines. Learn more here: https://lnkd.in/gdd5zsRy https://lnkd.in/gnh5ffY8 #AI #BioTech #Healthcare #Innovation #Enchant

Today we are previewing our next-generation NeuralPLexer3 Beta AI model, which sets new standards for protein-ligand structure prediction – transforming structure determination from a bottleneck into a truly interactive tool for drug discovery. NeuralPLexer3 Beta enables researchers to explore therapeutic hypotheses with unprecedented accuracy and speed. Trained on datasets encompassing a vast array of biologic structures and interaction types, the new model provides researchers instant, accurate structural insights across the full range of protein classes and drug molecules. This next version of NeuralPLexer is a significant step toward fully AI-enabled structure-based drug design. Learn more here: https://lnkd.in/gyiGdKZy #AI #BioTech #Healthcare #Innovation #NeuralPLexer

Quite a week for technology at Iambic Therapeutics! Following Tuesday's launch of Enchant, the multimodal transformer for drug discovery, we're excited to give an early preview of NeuralPLexer3 Beta, the next generation of our state-of-the-art technology for predicting 3D protein-ligand structures. These two breakthroughs in #AI driven #drugdiscovery are helping our scientists to power our internal and partnered drug-discovery pipeline. Of course stories like these don't just happen: they come from the creativity and dedicated work of a large group of machine learning scientists, software engineers and cloud engineers, and I thank all of those at Iambic who contributed to these advances. NeuralPLexer3 Beta: https://lnkd.in/esK4TRGg Enchant: https://lnkd.in/erJfTsU7

Today we are previewing our next-generation NeuralPLexer3 Beta AI model, which sets new standards for protein-ligand structure prediction – transforming structure determination from a bottleneck into a truly interactive tool for drug discovery. NeuralPLexer3 Beta enables researchers to explore therapeutic hypotheses with unprecedented accuracy and speed. Trained on datasets encompassing a vast array of biologic structures and interaction types, the new model provides researchers instant, accurate structural insights across the full range of protein classes and drug molecules. This next version of NeuralPLexer is a significant step toward fully AI-enabled structure-based drug design. Learn more here: https://lnkd.in/gyiGdKZy #AI #BioTech #Healthcare #Innovation #NeuralPLexer

Iambic’s newly introduced multi-modal AI model for drug discovery and development, called Enchant, is designed to bring higher quality medicines to patients faster by predicting clinical outcomes from the earliest stages of discovery -- potentially eliminating years of preclinical discovery and accelerating clinical trial timelines. Learn more here: https://lnkd.in/gdd5zsRy https://lnkd.in/gnh5ffY8 #AI #BioTech #Healthcare #Innovation #Enchant

See today's Reuters piece by Martin Coulter about our launch of "Enchant", a state-of-the art multi-modal AI model that predicts clinical properties of potential medicines from the earliest stages of drug discovery. Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’. https://lnkd.in/gd2Y3Y7j #AI #BioTech #Healthcare #Innovation #Enchant

Introducing Enchant™, our groundbreaking multimodal AI model designed to predict clinical outcomes from the earliest stages of drug discovery. Pushing through the R&D "data wall," Enchant leverages abundant discovery-stage data with small amounts of human data to better predict key clinical properties of drug candidates at the earliest stages of research. See today's white paper and press release describing how our state-of-the-art multi-modal transformer model provides predictive insights into pharmacokinetics and other drug properties to reduce cost and increase the quality of clinical drug candidates. #AI #BioTech #Healthcare #Innovation #Enchant https://lnkd.in/gdd5zsRy https://lnkd.in/gzxhcb4H